Formycon AG
19.06
EUR
-0.46
(-2.36%)
ISIN
DE000A1EWVY8
Return %
Stock
S&P 500
1Y
-19.58
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Stefan Glombitza
- Full Time Employees
- 203
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Fraunhoferstrasse 15 Munich BV Germany 82152
- IPO Date
- Dec 20, 2010
- Website
- formycon.com
- Similar Companies
- Business
- Formycon AG is a Germany-based biopharmaceutical company specializing in the development and commercialization of high-quality biosimilars, which are follow-on versions of biopharmaceutical medicines already on the market. The company’s core products include biosimilars for ophthalmology treatments such as ranibizumab and aflibercept marketed under brand names like Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza; immunology biosimilars including ustekinumab under the Otulf, Fymskina, and Sitovab brands; as well as biosimilars targeting oncology and immuno-oncology with development candidates like pembrolizumab and dupilumab (FYB208). Its products address therapeutic areas such as neovascular age-related macular degeneration, diabetic macular edema, autoimmune diseases, Crohn's disease, ulcerative colitis, psoriasis, and various cancers. Formycon’s activities cover technical pharmaceutical development, clinical trials, regulatory submissions, and global commercialization, operating primarily in Europe and North America. Founded in 2002 and headquartered in Planegg, Germany, Formycon has positioned itself as a leading independent biosimilar developer with an extensive and robust intellectual property portfolio. The company strategically partners with established pharmaceutical firms like STADA Arzneimittel AG and Fresenius Kabi to enhance market access and commercial capabilities. Recent major changes include a 2025 settlement and license agreement with Regeneron Pharmaceuticals resolving patent disputes on the FDA-approved Eylea biosimilar; the launch of the ranibizumab biosimilar Epruvy® in Germany; and the announcement in late 2025 of development progress on FYB208, a dupilumab biosimilar candidate targeting key immunological indications. Formycon also reported strategic cost reductions and operational enhancements in its 2025 financial results while maintaining focus on accelerating revenue growth from its expanding biosimilar portfolio. Formycon’s pipeline reflects ongoing expansion with late-stage development of FYB201 (a biosimilar to Lucentis) and FYB203 (targeting autoimmune diseases), alongside advancing FYB208 for immunology and other biosimilar candidates like FYB209. The company’s strategic roadmap emphasizes sustainable profitability and geographic market enlargement, backed by continuous innovation and regulatory compliance efforts. Its products and pipeline address significant unmet medical needs in chronic and complex conditions, underscoring Formycon’s role in improving healthcare accessibility through affordable biologic treatments globally. The company’s foundational and recent operational progress underpin its market positioning as a dynamic innovator in the global biosimilars industry.